270 related articles for article (PubMed ID: 28315359)
1. Antibodies and associates: Partners in targeted drug delivery.
Kennedy PJ; Oliveira C; Granja PL; Sarmento B
Pharmacol Ther; 2017 Sep; 177():129-145. PubMed ID: 28315359
[TBL] [Abstract][Full Text] [Related]
2. Antibody-drug conjugates for cancer therapy: The technological and regulatory challenges of developing drug-biologic hybrids.
Hamilton GS
Biologicals; 2015 Sep; 43(5):318-32. PubMed ID: 26115630
[TBL] [Abstract][Full Text] [Related]
3. Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells.
Cirstoiu-Hapca A; Buchegger F; Bossy L; Kosinski M; Gurny R; Delie F
Eur J Pharm Sci; 2009 Oct; 38(3):230-7. PubMed ID: 19632322
[TBL] [Abstract][Full Text] [Related]
4. Antibody-conjugated nanoparticles for therapeutic applications.
Cardoso MM; Peça IN; Roque AC
Curr Med Chem; 2012; 19(19):3103-27. PubMed ID: 22612698
[TBL] [Abstract][Full Text] [Related]
5. Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles.
Cirstoiu-Hapca A; Bossy-Nobs L; Buchegger F; Gurny R; Delie F
Int J Pharm; 2007 Mar; 331(2):190-6. PubMed ID: 17196347
[TBL] [Abstract][Full Text] [Related]
6. Antibody-drug conjugates in cancer therapy.
Sievers EL; Senter PD
Annu Rev Med; 2013; 64():15-29. PubMed ID: 23043493
[TBL] [Abstract][Full Text] [Related]
7. Arming antibodies: prospects and challenges for immunoconjugates.
Wu AM; Senter PD
Nat Biotechnol; 2005 Sep; 23(9):1137-46. PubMed ID: 16151407
[TBL] [Abstract][Full Text] [Related]
8. Targeting HER2+ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles.
Owen SC; Patel N; Logie J; Pan G; Persson H; Moffat J; Sidhu SS; Shoichet MS
J Control Release; 2013 Dec; 172(2):395-404. PubMed ID: 23880472
[TBL] [Abstract][Full Text] [Related]
9. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
Vincent KJ; Zurini M
Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
[TBL] [Abstract][Full Text] [Related]
10. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
11. Antibody conjugate therapeutics: challenges and potential.
Teicher BA; Chari RV
Clin Cancer Res; 2011 Oct; 17(20):6389-97. PubMed ID: 22003066
[TBL] [Abstract][Full Text] [Related]
12. Controlled-release and local delivery of therapeutic antibodies.
Grainger DW
Expert Opin Biol Ther; 2004 Jul; 4(7):1029-44. PubMed ID: 15268671
[TBL] [Abstract][Full Text] [Related]
13. Polyester-Based Nanoparticles for the Encapsulation of Monoclonal Antibodies.
Sousa F; Fonte P; Cruz A; Kennedy PJ; Pinto IM; Sarmento B
Methods Mol Biol; 2018; 1674():239-253. PubMed ID: 28921443
[TBL] [Abstract][Full Text] [Related]
14. Theranostic nanoparticles carrying doxorubicin attenuate targeting ligand specific antibody responses following systemic delivery.
Yang E; Qian W; Cao Z; Wang L; Bozeman EN; Ward C; Yang B; Selvaraj P; Lipowska M; Wang YA; Mao H; Yang L
Theranostics; 2015; 5(1):43-61. PubMed ID: 25553097
[TBL] [Abstract][Full Text] [Related]
15. Technology insight: cytotoxic drug immunoconjugates for cancer therapy.
Ricart AD; Tolcher AW
Nat Clin Pract Oncol; 2007 Apr; 4(4):245-55. PubMed ID: 17392715
[TBL] [Abstract][Full Text] [Related]
16. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.
Vezina HE; Cotreau M; Han TH; Gupta M
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650
[TBL] [Abstract][Full Text] [Related]
17. When liposomes met antibodies: Drug delivery and beyond.
Di J; Xie F; Xu Y
Adv Drug Deliv Rev; 2020; 154-155():151-162. PubMed ID: 32926944
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of nanoparticle-antibody conjugations: carbodiimide versus click chemistry.
Thorek DL; Elias DR; Tsourkas A
Mol Imaging; 2009; 8(4):221-9. PubMed ID: 19728976
[TBL] [Abstract][Full Text] [Related]
19. [An overview of antibody-based cancer therapy].
Miao QF; Shao RG; Zhen YS
Yao Xue Xue Bao; 2012 Oct; 47(10):1261-8. PubMed ID: 23289136
[TBL] [Abstract][Full Text] [Related]
20. Antibody-targeted drugs and drug resistance--challenges and solutions.
Shefet-Carasso L; Benhar I
Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
